04/25/2017 - 9:23am

For its 2017 fiscal fourth quarter ended March 4, Rite Aid reported revenues of $8.5 billion and a net loss of $21.1 million. Its adjusted net loss came in at $3.2 million, which bested Wall Street estimates.

04/20/2017 - 3:04pm

Drugs are used for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist combination.

04/20/2017 - 10:07am

Japanese generic pharmaceutical manufacturer Sawai Pharmaceutical will purchase the assets and plans a major expansion in the U.S. market.

04/19/2017 - 5:31pm

According to Argentum, the agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering Restasis. 

04/18/2017 - 1:08pm

In fact, J&J stated is now including the estimated impact of the Actelion transaction in its financial guidance.

04/18/2017 - 9:51am

Tecentriq (atezolizumab) was granted accelerated approval for the treatment of people with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.

04/14/2017 - 2:51pm

State senators voted 22-9 in favor of approving a measure intended to help ease the state’s growing opioid epidemic.

04/12/2017 - 9:47am

Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips.

04/10/2017 - 12:42pm

Company hopes to raise up to $100 million and list on the New York Stock Exchange under the ticker symbol BHVN.